Fee and Kasarskis12 described a 66-yearold- diabetic man who developed facial weakness and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had an elevated titer of acetylcholine receptor antibodies (AChR-Ab), and electrophysiologic studies suggested a disorder of neuromuscular transmission associated with axonal polyneuropathy. No immunomodulating therapy was given. After 3–8 months off etanercept his clinical and electrophysiologic features improved, but AChR-Ab titer remained elevated. We recently encountered a 68-year-old woman who experienced fluctuating fatigability 7–8 months after starting etanercept (Enbrel; Wyeth Lederle SpA) taken weekly (50 mg autoinjected subcutaneously) to treat psoriatic arthritis.
Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue / G., Galassi; A., Ariatti; L., Codeluppi; Meletti, Stefano. - In: MUSCLE & NERVE. - ISSN 0148-639X. - STAMPA. - 42:2(2010), pp. 296-298. [10.1002/mus.21748]
Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue.
MELETTI, Stefano
2010
Abstract
Fee and Kasarskis12 described a 66-yearold- diabetic man who developed facial weakness and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had an elevated titer of acetylcholine receptor antibodies (AChR-Ab), and electrophysiologic studies suggested a disorder of neuromuscular transmission associated with axonal polyneuropathy. No immunomodulating therapy was given. After 3–8 months off etanercept his clinical and electrophysiologic features improved, but AChR-Ab titer remained elevated. We recently encountered a 68-year-old woman who experienced fluctuating fatigability 7–8 months after starting etanercept (Enbrel; Wyeth Lederle SpA) taken weekly (50 mg autoinjected subcutaneously) to treat psoriatic arthritis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2010_Muscle&Nerve.pdf
Accesso riservato
Descrizione: articolo in pdf
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
131.65 kB
Formato
Adobe PDF
|
131.65 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
